Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 nov. 2025 06h00 HE | Source: Anteris Technologies Global Corp.

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves
12 nov. 2025 17h52 HE | Source: Anteris Technologies Global Corp.

Anteris Announces Results for the Third Quarter of 2025

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reports financial results for the quarter ended September 30, 2025, and provides a corporate update.
03 nov. 2025 07h00 HE | Source: Anteris Technologies Global Corp.

FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and...
27 oct. 2025 17h43 HE | Source: Anteris Technologies Global Corp.

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Technologies Announces First Patients Treated in the DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
15 oct. 2025 09h18 HE | Source: Anteris Technologies Global Corp.

Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)